S3 Ep11: Speaking Out on Non-Small Cell Lung Cancers
Cancer Horizons27 Feb 2020

S3 Ep11: Speaking Out on Non-Small Cell Lung Cancers

While the treatment landscape for non-small cell lung cancer (NSCLC) continues to evolve, there is a heavy emphasis on discovering new targeted therapies for patients. Because of this, it is key for patients to have their tumors tested for biomarkers to determine if they have a mutation, like EGFR, ROS1, ALK, BRAF, that could determine what treatment they should undergo. For example, Tagrisso (osimertinib) is approved by the Food and Drug Administration to treat patients with NSCLC with an EGFR mutation. In this episode, we spoke with Andrew Ciupek, manager of clinical research at the Go2 Foundation for Lung Cancer, to learn more about biomarker testing and the various treatment options available for patients with NSCLC.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(295)

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

CURE sat down with Dr. Natalie S. Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berg...

31 Des 202514min

S7 Ep1: The Importance of Spotting Endometrial Cancer

S7 Ep1: The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.

18 Mar 202510min

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

17 Sep 202419min

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we’ll discuss another ca...

4 Mar 20247min

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, an...

4 Mar 202410min

S6 Ep20: FDA Approvals from February 2024

S6 Ep20: FDA Approvals from February 2024

Last week, the Food and Drug Administration (FDA) approved four different therapies in the oncology space — one of which, Amtagvi, marks the first cellular therapy for the treatment of solid cancers. ...

23 Feb 20246min

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tum...

19 Feb 20249min

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered researc...

12 Feb 20247min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
jss
liberal-halvtime
rekommandert
forskningno
villmarksliv
sinnsyn
tomprat-med-gunnar-tjomlid
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
fjellsportpodden
rss-rekommandert
vett-og-vitenskap-med-gaute-einevoll
dekodet-2
rss-nysgjerrige-norge
smart-forklart
nevropodden
diagnose
rss-paradigmepodden
abels-tarn